Results 161 to 170 of about 147,672 (267)
Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Vascular Changes Induced by Sunitinib in Papillary Renal Cell Carcinoma Xenograft Tumors
, 2009 Gilda G. Hillman, Vinita Singh‐Gupta, Hao Zhang, Areen K. Al‐Bashir, Yashwanth Katkuri, Meng Li, Christopher K. Yunker, A. Patel, Judith Abrams, E. Mark Haacke +9 moreopenalex +1 more sourceComprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma. [PDF]
J Immunother Cancer, 2023 de Vries-Brilland M, Rioux-Leclercq N, Meylan M, Dauvé J, Passot C, Spirina-Menand E, Flippot R, Fromont G, Gravis G, Geoffrois L, Chevreau C, Rolland F, Blanc E, Lefort F, Ravaud A, Gross-Goupil M, Escudier B, Negrier S, Albiges L. +18 moreeuropepmc +1 more sourcePapillary Renal Cell Carcinoma: Demographics, Survival Analysis, Racial Disparities, and Genomic Landscape. [PDF]
J Kidney Cancer VHL, 2023 Ullah A, Yasinzai AQK, Daino N, Tareen B, Jogezai ZH, Sadia H, Jamil N, Baloch G, Karim A, Badini K, Wali A, Waheed A, Khan M, Asif B, Kakar K, Heneidi S, Sidhwa F, Karki NR. +17 moreeuropepmc +1 more sourceFirst Line Sunitinib in Type I and II Papillary Renal Cell Carcinoma (PRCC): Supap- A Phase II Study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase Trials (GEP)
, 2012 Alain Ravaud, Stéphane Oudard, Marc de Fromont, Christine Chevreau, Gwénaëlle Gravis, Sylvie Zanetta, Christine Théodore, Marta Jimenez, Emmanuel Sevin, Bernard Escudier +9 moreopenalex +1 more sourceOpen-Label Phase II Trial of First-Line Everolimus Monotherapy in Patients with Advanced Papillary Renal Cell Carcinoma: Raptor Interim Analysis
, 2012 Bernard Escudier, Sergio Bracarda, Pablo Maroto, Cezary Szczylik, Paul Nathan, S. Négrier, K. Slimane, Christoph May, Camillo Porta, Viktor Grünwald +9 moreopenalex +1 more source